Proteomics in Parkinson’s disease: current trends, translational snags and future possibilities

References

• Singh MP, Patel S, Dikshit M, Gupta YK. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson’s disease. Indian J. Biochem. Biophys.43(2), 69–81 (2006).
   PubMed Web of Science ®Google Scholar
• Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci.14(2), 223–236 (2002).
   PubMed Web of Science ®Google Scholar
• Singh S, Dikshit M. Apoptotic neuronal death in Parkinson’s disease: involvement of nitric oxide. Brain Res. Rev.54(2), 233–250 (2007).
   PubMed Web of Science ®Google Scholar
• Caronti G, Antonini C, Calderaro S et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson’s disease. J. Neural. Transm.108, 803–807(2001).
   PubMed Web of Science ®Google Scholar
• Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog. Neurobiol.69(3), 193–211(2003).
   PubMed Web of Science ®Google Scholar
• Kim S, Jeon BS, Heo C et al. α-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J.18(13), 1615–1617 (2004).
   PubMed Web of Science ®Google Scholar
• Licker V, Kövari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinson’s disease research. J. Proteomics73(1), 10–29 (2009).
   PubMed Web of Science ®Google Scholar
• Sowell RA, Owen JB, Butterfield DA. Proteomics in animal models of Alzheimer’s and Parkinson’s diseases. Ageing Res. Rev.8(1), 1–17 (2009)
   PubMed Web of Science ®Google Scholar
• Fasano M, Lopiano L. α-synuclein and Parkinson's disease: a proteomic view. Expert Rev. Proteomics5(2), 239–248 (2008).
   PubMed Web of Science ®Google Scholar
• Pienaar IS, Daniels WM, Götz J. Neuroproteomics as a promising tool in Parkinson’s disease research. J. Neural. Transm.115(10), 1413–1430 (2008).
   PubMed Web of Science ®Google Scholar
• Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology72(7), S27–S31 (2009).
   PubMed Web of Science ®Google Scholar
• Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis.35(2), 157–164 (2009).
   PubMed Web of Science ®Google Scholar
• Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics4(12), 3943–3952 (2004).
   PubMed Web of Science ®Google Scholar
• Sinha A, Patel S, Shukla R, Singh MP. Blood proteome profiling in case controls and Parkinson’s disease patients in Indian population. Clin. Chim. Acta380(1–2), 232–234 (2007).
   PubMed Web of Science ®Google Scholar
• Sinha A, Srivastava N, Singh S et al. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson’s disease patients: a proteomic approach. Clin. Chim. Acta400(1–2), 14–20 (2009).
   PubMed Web of Science ®Google Scholar
• Patel S, Sinha A, Singh MP. Identification of differentially expressed proteins in striatum of maneb- and paraquat-induced Parkinson’s disease phenotype in mouse. Neurotoxicol. Teratol.29(5), 578–585 (2007).
   PubMed Web of Science ®Google Scholar
• Leighton JK. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives. Int. J. Toxicol.24(3), 153–155 (2005).
   PubMed Web of Science ®Google Scholar
• Hynd MR, Lewohl JM, Scott HL, Dodd PR. Biochemical and molecular studies using human autopsy brain tissue. J. Neurochem.85(3), 543–562 (2003).
   PubMed Web of Science ®Google Scholar
• Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson’s disease. Brain127(8), 1693–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Mitchell A, Brindle N. CSF phosphorylated tau – does it constitute an accurate biological test for Alzheimer’s disease? Int. J. Geriatr. Psychiatry18(5), 407–411 (2003).
   PubMed Web of Science ®Google Scholar
• Hodgetts A, Levin M, Kroll JS, Langford PR. Biomarker discovery in infectious diseases using SELDI. Future Microbiol.2(1), 35–49 (2007).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov.1(9), 683–695 (2002).
   PubMed Web of Science ®Google Scholar
• Graeber MB. Biomarkers for Parkinson’s disease. Exp. Neurol.216(2), 249–253 (2009).
   PubMed Web of Science ®Google Scholar
• Fasano M, Alberio T, Lopiano L. Peripheral biomarkers of Parkinson’s disease as early reporters of central neurodegeneration. Biomarker Med.2(5), 465–478 (2008).
   PubMed Web of Science ®Google Scholar
• Antoniades CA, Barker RA. The search for biomarkers in Parkinson’s disease: a critical review. Expert Rev. Neurother.8(12), 1841–1852 (2008).
   PubMedGoogle Scholar
• Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA. CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics2(1), 57–70 (2005).
   PubMed Web of Science ®Google Scholar
• Waragai M, Wei J, Fujita M et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem. Biophys. Res. Commun.345(3), 967–972 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dang C, Ma Q, Shimahara Y. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol. Rep.14(1), 161–171(2005).
   PubMed Web of Science ®Google Scholar
• Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol.129(4), 526–529 (2008).
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J.20(3), 419–425 (2006).
   PubMed Web of Science ®Google Scholar
• Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res.7(2), 720–730 (2008).
   PubMed Web of Science ®Google Scholar
• Sheta EA, Appel SH, Goldknopf IL. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev. Proteomics3(1), 45–62 (2006).
   PubMed Web of Science ®Google Scholar
• Goldknopf IL, Sheta EA, Bryson J et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson’s disease. Biochem. Biophys. Res. Commun.342(4), 1034–1039 (2006).
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Takeda A, Onodera H et al. Systemic increase of oxidative nucleic acid damage in Parkinson’s disease and multiple system atrophy. Neurobiol. Dis.9(2), 244–248 (2002).
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Hara K, Sethi KD, Morgan JC, Borlongan CV. Increased 8-OHdG levels in the urine, serum and substantia nigra of hemiparkinsonian rats. Brain Res.1133(1), 49–52 (2007).
   PubMed Web of Science ®Google Scholar
• Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson’s disease patients. Funct. Neurol.4(3), 141–147 (1999)
   Google Scholar
• Drouot X, Moutereau S, Nguyen JP et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology61(4), 540–543 (2003).
   PubMed Web of Science ®Google Scholar
• Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers21(2), 93–101 (2005).
   PubMed Web of Science ®Google Scholar
• Nagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: role for cytokines. Curr. Pharm. Des.11(8), 999–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Mila S, Albo AG, Corpillo D et al. Lymphocyte proteomics of Parkinson’s disease patients reveals cytoskeletal protein dysregulation and oxidative stress. Biomarker Med.3(2), 117–128 (2009).
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Pendyala G, Siuzdak G, Fox HS. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J. Clin. Invest.118(7), 2661–2669 (2008).
   PubMed Web of Science ®Google Scholar
• Cairns DA, Barrett JH, Billingham LJ et al. Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics9(1), 74–86 (2009).
   PubMed Web of Science ®Google Scholar
• Wu Q, Maniatis T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell97(6), 779–790 (1999).
   PubMed Web of Science ®Google Scholar
• Tribl F, Marcus K, Meyer HE, Bringmann G, Gerlach M, Riederer P. Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J. Neural. Transm.113(6), 741–749 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids25(3–4), 419–425 (2003).
   PubMed Web of Science ®Google Scholar
• Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci.6, 8 (2008).
   PubMed Web of Science ®Google Scholar
• Patt S, Gertz HJ, Gerhard L, Cervós-Navarro J. Pathological changes in dendrites of substantia nigra neurons in Parkinson’s disease: a Golgi study. Histol. Histopathol.6(3), 373–380 (1991).
   PubMed Web of Science ®Google Scholar
• Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3, 4-dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res.989(2), 205–213 (2003).
   PubMed Web of Science ®Google Scholar
• Tobin JE, Cui J, Wilk JB et al. Sepiapterin reductase expression is increased in Parkinson’s disease brain tissue. Brain Res.1139, 42–47 (2007).
   PubMed Web of Science ®Google Scholar
• Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson’s disease? Investigations by magnetic spectroscopies. J. Neural. Transm.113(6), 769–774 (2006).
   PubMed Web of Science ®Google Scholar
• Grimm J, Mueller A, Hefti F, Rosenthal A. Molecular basis for catecholaminergic neuron diversity. Proc. Natl Acad. Sci. USA101(38), 13891–13896 (2004).
   PubMed Web of Science ®Google Scholar
• Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science219(4587), 979–980 (1983).
   PubMed Web of Science ®Google Scholar
• Patel S, Singh K, Singh S, Singh MP. Gene expression profiles of mouse striatum in control and maneb + paraquat-induced Parkinson’s disease phenotype: validation of differentially expressed energy metabolizing transcripts. Mol. Biotechnol.40(1), 59–68 (2008).
   PubMed Web of Science ®Google Scholar
• Thiruchelvam M, Richfield EK, Goodman BM, Baggs RB, Cory-Slechta DA. Developmental exposure to the pesticides paraquat and maneb and the Parkinson’s disease phenotype. Neurotoxicology23(4–5), 621–633 (2002).
   PubMed Web of Science ®Google Scholar
• Liu J, Zhou Y, Wang Y, Fong H, Murray TM, Zhang J. Identification of proteins involved in microglial endocytosis of α-synuclein. J. Proteome Res.6(9), 3614–3627 (2007).
   PubMed Web of Science ®Google Scholar
• Przedborski S, Chen Q, Vila M et al. Oxidative post-translational modifications of α-synuclein in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease. J. Neurochem.76(2), 637–640 (2001).
   PubMed Web of Science ®Google Scholar
• Jin J, Meredith GE, Chen L et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson’s disease. Brain Res. Mol. Brain Res.134(1), 119–138 (2005).
   PubMedGoogle Scholar
• McLaughlin P, Zhou Y, Ma T et al. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia53(6), 567–582 (2006).
   PubMed Web of Science ®Google Scholar
• Svensson M, Sköld K, Nilsson A, Fälth M, Svenningsson P, Andrén PE. Neuropeptidomics: expanding proteomics downwards. Biochem. Soc. Trans.35(Pt 3), 588–593 (2007).
   PubMed Web of Science ®Google Scholar
• Ara J, Przedborski S, Naini AB et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl Acad. Sci. USA95(13), 7659–7663 (1998).
   PubMed Web of Science ®Google Scholar
• Ungerstedt U. 6-hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol.5(1), 107–110 (1968).
   PubMed Web of Science ®Google Scholar
• Luthman J, Fredriksson A, Sundström E, Jonsson G, Archer T. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav. Brain Res.33(3), 267–277 (1989).
   PubMed Web of Science ®Google Scholar
• Pierson J, Svenningsson P, Caprioli RM, Andren PE. Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats. J. Proteome Res.4(2), 223–226 (2005).
   PubMed Web of Science ®Google Scholar
• Elkon H, Melamed E, Offen D. 6-hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson’s disease. Cell. Mol. Neurobiol.21(6), 771–781 (2001).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yamada M, Ohsawa T et al. Phosphoproteomic profiling of human SH-SY5Y neuroblastoma cells during response to 6-hydroxydopamine-induced oxidative stress. Biochim. Biophys. Acta1763(9), 977–989 (2006).
   PubMed Web of Science ®Google Scholar
• Choi WS, Yoon SY, Oh TH, Choi EJ, O’Malley KL, Oh YJ. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res.57(1), 86–94 (1999).
   PubMed Web of Science ®Google Scholar
• Lee YM, Park SH, Shin DI et al. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J. Biol. Chem.283(15), 9986–9998 (2008).
   PubMed Web of Science ®Google Scholar
• Saito Y, Nishio K, Ogawa Y et al. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Free Radic. Biol. Med.42(5), 675–685 (2007).
   PubMed Web of Science ®Google Scholar
• Shen Y, Yu Y, Guo H, Tang Z, Yu FS, Zhou J. Identification and comparative analysis of differentially expressed proteins in rat striatum following 6-hydroxydopamine lesions of the nigrostriatal pathway: up-regulation of amyloid precursor-like protein 2 expression. Eur. J. Neurosci.16(5), 896–906 (2002).
   PubMed Web of Science ®Google Scholar
• Nilsson A, Sköld K, Sjögren B et al. Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinson’s disease and identification of FKBP-12-binding proteins. J. Proteome Res.6(10), 3952–3961 (2007).
   PubMed Web of Science ®Google Scholar
• Lee YM, Park SH, Chung KC, Oh YJ. Proteomic analysis reveals upregulation of calreticulin in murine dopaminergic neuronal cells after treatment with 6-hydroxydopamine. Neurosci. Lett.352(1), 17–20 (2003).
   PubMed Web of Science ®Google Scholar
• Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein. J. Biol. Chem.277(3), 1641–1644 (2002).
   PubMed Web of Science ®Google Scholar
• Miller RL, Sun GY, Sun AY. Cytotoxicity of paraquat in microglial cells: Involvement of PKC-δ and ERK1/2-dependent NADPH oxidase. Brain Res.1167, 129–139 (2007).
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Carrard G, Michel PP et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J. Neurochem.86(5), 1297–1307 (2003).
   PubMed Web of Science ®Google Scholar
• Wang XF, Li S, Chou AP, Bronstein JM. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol. Dis.23(1), 198–205 (2006).
   PubMed Web of Science ®Google Scholar
• Casarejos MJ, Menéndez J, Solano RM, Rodríguez-Navarro JA, García de Yébenes J, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem.97(4), 934–946 (2006).
   PubMed Web of Science ®Google Scholar
• Wang C, Ko HS, Thomas B et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum. Mol. Genet.14(24), 3885–3897 (2005).
   PubMed Web of Science ®Google Scholar
• Terzioglu M, Galter D. Parkinson’s disease: genetic versus toxin-induced rodent models. FEBS J.275(7), 1384–1391 (2008).
   PubMed Web of Science ®Google Scholar
• Chesselet MF, Fleming S, Mortazavi F, Meurers B. Strengths and limitations of genetic mouse models of Parkinson’s disease. Parkinsonism Relat. Disord.14(2), S84–S87 (2008).
   PubMedGoogle Scholar
• Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik26(3), 231–243 (1975).
   PubMedGoogle Scholar
• O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem.250(10), 4007–4021 (1975).
   PubMed Web of Science ®Google Scholar
• Klose J, Nock C, Herrmann M et al. Genetic analysis of the mouse brain proteome. Nat. Genet.30(4), 385–393 (2002).
   PubMed Web of Science ®Google Scholar
• Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggins JN, Harrington MG. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis. Markers22(1–2), 39–64 (2006).
   PubMed Web of Science ®Google Scholar
• Morón JA, Devi LA. Use of proteomics for the identification of novel drug targets in brain diseases. J. Neurochem.102(2), 306–315 (2007).
   PubMed Web of Science ®Google Scholar
• Görg A, Weiss W, Dunn MJ. Current 2D electrophoresis technology for proteomics. Proteomics4(12), 3665–3685 (2004).
   PubMed Web of Science ®Google Scholar
• Garbis S, Lubec G, Fountoulakis M. Limitations of current proteomics technologies. J. Chromatogr. A1077(1), 1–18 (2005).
   PubMed Web of Science ®Google Scholar
• Fountoulakis M. Proteomics: current technologies and applications in neurological disorders and toxicology. Amino Acids21(4), 363–381 (2001).
   PubMed Web of Science ®Google Scholar
• Marcus K, Schmidt O, Schaefer H, Hamacher M, van Hall A, Meyer HE. Proteomics – application to the brain. Int. Rev. Neurobiol.61, 285–311 (2004).
   PubMedGoogle Scholar
• Leverenz JB, Umar I, Wang Q et al. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol.17(2), 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Haab BB. Methods and applications of antibody microarrays in cancer research. Proteomics3(11), 2116–2122 (2003).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Sjögren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis. Markers21(2), 81–92 (2005).
   PubMed Web of Science ®Google Scholar
• Rite I, Argüelles S, Venero JL et al. Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. J. Neurosci. Res.85(16), 3607–3618 (2007).
   PubMed Web of Science ®Google Scholar
• Xia Q, Liao L, Cheng D et al. Proteomic identification of novel proteins associated with Lewy bodies. Front. Biosci.13, 3850–3856 (2008).
   PubMed Web of Science ®Google Scholar
• Tribl F, Asan E, Arzberger T et al. Identification of l-ferritin in neuromelanin granules of the human substantia nigra – a targeted proteomics approach. Mol. Cell. Proteomics8(8), 1832–1838 (2009).
   PubMed Web of Science ®Google Scholar
• Jin J, Hulette C, Wang Y et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics5(7), 1193–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Liu B, Shi Q, Ma S et al. Striatal 19S Rpt6 deficit is related to α-synuclein accumulation in MPTP-treated mice. Biochem. Biophys. Res. Commun.376(2), 277–282 (2008).
   PubMed Web of Science ®Google Scholar
• Xun Z, Sowell RA, Kaufman TC, Clemmer DE. Quantitative proteomics of a presymptomatic A53T α-synuclein Drosophila model of Parkinson disease. Mol. Cell. Proteomics7(7), 1191–1203 (2008).
   PubMed Web of Science ®Google Scholar
• Dukes AA, Van Laar VS, Cascio M, Hastings TG. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J. Neurochem.106(1), 333–346 (2008).
   PubMed Web of Science ®Google Scholar
• Diedrich M, Mao L, Bernreuther C et al. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics8(6), 1266–1275 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang L, Chang M, Li H et al. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res.1153, 196–203 (2007).
   PubMed Web of Science ®Google Scholar
• Xun Z, Sowell RA, Kaufman TC, Clemmer DE. Protein expression in a Drosophila model of Parkinson’s disease. J. Proteome Res.6(1), 348–357 (2007).
   PubMed Web of Science ®Google Scholar
• Sköld K, Svensson M, Nilsson A et al. Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J. Proteome Res.5(2), 262–269 (2006).
   PubMed Web of Science ®Google Scholar
• De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P. A proteomic approach in the study of an animal model of Parkinson’s disease. Clin. Chim. Acta357(2), 202–209 (2005).
   PubMed Web of Science ®Google Scholar